The FDA is changing how real world evidence is used in the pharmaceutical industry so that data collected outside clinical trials has become massively valuable. CB2 Insights' 28 clinics see 65,000 active uniques patients per year and are focused solely on cannabis medicine. CB2 Insights collects controlled data from those clinics using their proprietary technology and is applying predictive analytics to reveal the value in that data.

Presenting in this video is Prad Sekar, CEO of CB2 Insights.

Public listing expected mid- February CBII.CSE


Join us at an upcoming event! http://www.cambridgehouse.com

Be part of our investment community:
http://www.cambridgehouse.com/
https://twitter.com/cambridge
https://www.facebook.com/cambridgehouseconferences
https://www.linkedin.com/company/cambridge-house-international/

Copyright © 2019 Cambridge House International Inc. All rights reserved.